10-Q: Krystal Biotech Reports First Quarter 2024 Results, Driven by VYJUVEK Sales

Krystal Biotech's first quarter of 2024 saw a net income of $932,000, driven by $45.3 million in net product revenue from VYJUVEK.

Summary

• Krystal Biotech reported a net income of $932,000 for the first quarter of 2024, a significant improvement compared to a net loss of $45.3 million in the same period last year.
• The company's revenue was $45.3 million, all from sales of its FDA-approved product, VYJUVEK, which began commercial sales in the third quarter of 2023.
• Operating expenses totaled $51.9 million, including $2.4 million in cost of goods sold, $11 million in research and development, $26.1 million in selling, general, and administrative expenses, and $12.5 million for litigation settlement.
• The company's cash, cash equivalents, and short-term investments totaled $538.3 million as of March 31, 2024.
• Krystal Biotech believes its current cash position is sufficient to fund operations for at least the next 12 months.
• The company is progressing with clinical trials for other product candidates, including KB407 for cystic fibrosis, KB408 for alpha-1 antitrypsin deficiency, and KB707 for oncology.
• Krystal Biotech is also preparing for commercial launches in Europe and Japan, with a Marketing Authorization Application (MAA) under review by the EMA and a New Drug Application planned for submission in Japan in the second half of 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and progress in clinical trials. The company's financial position is solid, and the management's comments are optimistic. However, there are some risks and challenges that need to be addressed, such as the impact of the J-code switchover and the cybersecurity incident, and the ongoing litigation settlement.

Positives

• The company achieved profitability in the first quarter of 2024, driven by strong sales of VYJUVEK.
• VYJUVEK has achieved broad market access with 96% of covered lives having positive access.
• Patient compliance with VYJUVEK treatment is high, indicating good patient acceptance.
• The company is actively advancing its pipeline with multiple clinical trials underway.
• Krystal Biotech is expanding its commercial operations into Europe and Japan.
• The company has a strong cash position of $538.3 million, providing financial stability.

Negatives

• Product revenue was negatively impacted by the switchover to the permanent J-code and a cybersecurity incident at the specialty pharmacy provider, resulting in approximately 400 free vials being dispensed.
• The company incurred a $12.5 million litigation settlement expense related to the PeriphaGen agreement.
• The company continues to incur significant operating expenses, including research and development and selling, general, and administrative costs.

Risks

• The company's future success is heavily dependent on the continued commercial success of VYJUVEK.
• There are risks associated with the development and regulatory approval of the company's product candidates.
• The company faces competition from other companies developing therapies for the same indications.
• There are risks associated with manufacturing and supply chain management.
• The company is subject to various legal and regulatory risks, including product liability and healthcare fraud and abuse laws.
• The company's international operations expose it to various business, regulatory, and political risks.
• The company's internal computer systems and those of third parties are subject to cybersecurity risks.
• The company's operations are subject to environmental, health, and safety laws and regulations.
• The company is subject to U.S. and foreign export and import controls, anti-corruption laws and anti-money laundering laws and regulations.
• The company's operations and those of its customers, suppliers, third-party partners, and regulators could be adversely impacted by pandemics, epidemics, outbreaks of infectious diseases, or similar public health crises.

Future Outlook

The company expects to receive GMP certification from the EMA in the second half of 2024 and an EMA decision on its MAA in the second half of 2024. The company anticipates filing its Japan New Drug Application with Japans PMDA in the second half of 2024, enabling a potential authorization by PMDA in 2025. The company plans to initiate a Phase 2 study of KB301 following completion of the PEARL-1 Cohorts 3 and 4 studies. The company also plans to initiate a clinical trial of KB104 to treat patients with Netherton Syndrome following initiation of the KB105 Phase 2 study.

Management Comments

• Management intends to fund future operations through its on hand cash and cash equivalents, revenue generated from the sale of VYJUVEK, the sale of equity, and may also seek additional capital through arrangements with strategic partners, debt financings, or other sources.
• The Company believes that its cash, cash equivalents and short-term investments of approximately $538.3 million as of March 31, 2024 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.

Industry Context

This announcement reflects the ongoing trend of biotechnology companies focusing on gene therapy and rare diseases. Krystal Biotech's progress with VYJUVEK and its pipeline aligns with the industry's push for innovative treatments for unmet medical needs. The company's expansion into Europe and Japan also mirrors the global nature of the pharmaceutical market.

Comparison to Industry Standards

• Krystal Biotech's revenue of $45.3 million in the first quarter of 2024 is a strong start for a company that launched its first product in the third quarter of 2023. This is comparable to other biotech companies in the early stages of commercialization of a novel therapy.
• The company's cash position of $538.3 million is robust, providing a solid foundation for continued research and development and commercial expansion. This is a key metric for biotech companies, as it indicates the ability to fund operations and future growth.
• The company's progress with multiple clinical trials across different therapeutic areas is also a positive sign, indicating a diversified pipeline and potential for future growth. This is comparable to other companies with a similar focus on gene therapy.
• The company's expansion into Europe and Japan is a strategic move to capture a larger market share, which is a common strategy for biotech companies with global ambitions. This is comparable to other companies with a similar focus on gene therapy.
• The company's focus on rare diseases is also in line with the industry trend of developing treatments for unmet medical needs. This is a key area of focus for many biotech companies, as it offers the potential for high-value products and strong market exclusivity.
• The company's manufacturing capabilities are also a key differentiator, as it has two in-house commercial-scale CGMP facilities. This is a significant advantage over companies that rely on third-party manufacturers.

Management Changes

Legal Proceedings

• The company recorded a litigation settlement expense of $12.5 million for each of the three months ended March 31, 2024 and 2023 related to the settlement with PeriphaGen.
• The settlement agreement requires the company to pay three additional $12.5 million contingent milestone payments upon reaching $100.0 million, $200.0 million, and $300.0 million in total cumulative sales.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and progress in clinical trials.
• Employees will benefit from the company's growth and expansion.
• Patients will benefit from the company's development of new therapies for unmet medical needs.
• Customers will benefit from the company's commercialization of VYJUVEK and other product candidates.
• Suppliers and creditors will benefit from the company's financial stability and growth.

Next Steps

• The company intends to initiate the third and final cohort of the CORAL-1 Phase 1 study in the second quarter of 2024.
• The company intends to announce interim data from the SERPENTINE-1 study in the second half of 2024.
• The company plans to initiate a single-arm, open-label study for ophthalmic B-VEC in the second half of 2024.
• The company expects to report interim data from the OPAL-1 study before the end of the year.
• Jeune expects to announce results for both cohorts of the PEARL-1 study in mid-2024.
• Jeune plans to initiate a Phase 2 study of KB301 following completion of both cohorts of the PEARL-1 study.
• The company plans to file a PAS to the FDA in 2H 2024 for the scaled-up VYJUVEK manufacturing process.
• The company plans to file its Japan New Drug Application with Japans PMDA in the second half of 2024.

Key Dates

Keywords

VYJUVEK, gene therapy, dystrophic epidermolysis bullosa, DEB, cystic fibrosis, alpha-1 antitrypsin deficiency, oncology, clinical trials, biotechnology, pharmaceuticals, commercialization, FDA, EMA, manufacturing, J-code